Divalproex Sodium Tablet, Extended Release
Product Images NDC 70518-1138

Divalproex Sodium is a medication that comes in an extended-release tablet form with a strength of 250 mg. Each bottle contains 30 tablets, and it is available only with a prescription. The manufacturer is Dr. Reddy's, located in Shreveport, LA 71106, and the source NDC is 55111-0533-01. To maintain the efficacy of the medication, store it in a cool and dry place at 20-25°C (88-77°F), with excursions permitted between 15-30°C (59-86°F) [See USP]. The repackaging of the medication was done by RemedyRepack Ine., Indiana, PA 15701, and it is mandatory to keep it out of the reach of children. For more details on the usage of the medication, kindly read the Package Insert.*

This is a description of Divalproex Sodium Extended-Release tablets, with a dose of 250mg and a bottle containing 100 tablets. It is only available with a prescription and must be kept out of reach of children. The manufacturing company is Dr. Reddy's in Shreveport, LA with a source NDC of 55111-0533-05. The tablets should be stored at 20-25°C (88-77°F) with permitted excursions of 15-30°C (59-86°F) and the directions for use should be followed as per the package insert. Additionally, the tablets are repackaged by RemedyRepack Ine. in Indiana, PA.*

This is a bottle of Divalproex Sodium Extended-Release tablets, containing 250 mg each. It is a prescription medication that should be kept out of reach from children, and the user should read the package insert for directions on how to use it properly. It was manufactured by Dr. Reddy's in Shreveport and repackaged by RemedyRepack in Indiana, and the NDC number is 70518-1138-02. The lot number and expiration date are not available in the 'd text. The recommended storage temperature is between 20-25°C or 15-30°C.*

This appears to be a table of results showing the reduction in CPS (cycles per second) rate for patients taking high dose versus low dose Divalproex Sodium delayed-release tablets. The table shows that 50% of patients experienced an improvement in reducing CPS rate with high dose Divalproex Sodium, while there was no change in CPS rate for the other patients. However, without additional context, it is unclear what specific condition is being treated and how significant these results are.*

This description is not available as it is only a list of numbers and a partial drug name.*